J. Lipid Res.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cao, H.
Right arrow Articles by Moulin, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cao, H.
Right arrow Articles by Moulin, P.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
The Journal of Lipid Research, Vol. 40, 133-139, January 1999
Copyright © 1999 by Lipid Research, Inc.


Original Article

Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q->R genetic polymorphism

Huibi Caoa, Anik Girard-Globaa,b, Francois Berthezenec, and Philippe Moulina,c
a Laboratoire de Métabolisme des Lipides, Université Lyon 1, Hôpital de l'Antiquaille, F-69005 Lyon
b CNRS-UPRESA 5014, Université Lyon 1, Faculté de Médecine et de Pharmacie, F-69007 Lyon
c Department of Endocrinology and Metabolic Diseases, Hôpital de l'Antiquaille, F-69005 Lyon, France

Correspondence to: Philippe Moulin

High density lipoprotein (HDL)-associated paraoxonase (PON) seems to play a major role in the protection of low density lipoprotein (LDL) against peroxidation by HDL, and the partly purified enzyme exerts a dose-dependent protective effect. A common polymorphism of the human gene (192 Q->R) modulates paraoxonase activity but purified enzyme from either genotype is equally effective against LDL peroxidation. The inhibition of Cu2+-induced LDL peroxidation by HDL was monitored by lipid peroxide assay and change in LDL electrophoretic mobility. We show that HDL from type 2 diabetic patients with the QQ or RR genotype (n = 12 for each) reduce, to the same extent, both peroxide production (by 60.6 ± 20.0 and 63.9 ± 23.5%) and relative change in mobility (61.3 ± 21.8 and 61.4 ± 26.5%) despite a 6-fold difference in paraoxonase activity (47.4 ± 4.4 vs. 299.7 ± 23.7 U/l, P < 0.0001). Protection was, however, related to paraoxonase activity, but with a different efficiency in each group corresponding to a better protection per unit of enzyme in the QQ genotype group. Inactivation of PON activity by heating (56°C, 10 min) or by EDTA was totally without effect on protection, which remained correlated with the paraoxonase activity measured prior to inactivation.

In summary, these results suggest that the protein bearing both paraoxonase and arylesterase activities also possesses a third thermostable property, closely associated with paraoxon hydrolysis activity and unaffected by PON genetic variability.—Cao, H., A. Girard-Globa, F. Berthezene, and P. Moulin. Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q->R genetic polymorphism. J. Lipid Res. 1999. 40: 133–139.

Supplementary key words: paraoxonase, HDL, LDL, peroxidation, atherosclerosis


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J PsychopharmacolHome page
A. Sarandol, S. Kirli, C. Akkaya, N. Ocak, E. Eroz, and E. Sarandol
Coronary artery disease risk factors in patients with schizophrenia: effects of short term antipsychotic treatment
J Psychopharmacol, November 1, 2007; 21(8): 857 - 863.
[Abstract] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. Deakin, X. Moren, and R. W. James
HDL Oxidation Compromises its Influence on Paraoxonase-1 Secretion and its Capacity to Modulate Enzyme Activity
Arterioscler. Thromb. Vasc. Biol., May 1, 2007; 27(5): 1146 - 1152.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. Kriska, G. K. Marathe, J. C. Schmidt, T. M. McIntyre, and A. W. Girotti
Phospholipase Action of Platelet-activating Factor Acetylhydrolase, but Not Paraoxonase-1, on Long Fatty Acyl Chain Phospholipid Hydroperoxides
J. Biol. Chem., January 5, 2007; 282(1): 100 - 108.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. Graner, R. W. James, J. Kahri, M. S. Nieminen, M. Syvanne, and M.-R. Taskinen
Association of Paraoxonase-1 Activity and Concentration With Angiographic Severity and Extent of Coronary Artery Disease
J. Am. Coll. Cardiol., June 20, 2006; 47(12): 2429 - 2435.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
J. F. Teiber, D. I. Draganov, and B. N. La Du
Purified human serum PON1 does not protect LDL against oxidation in the in vitro assays initiated with copper or AAPH
J. Lipid Res., December 1, 2004; 45(12): 2260 - 2268.
[Abstract] [Full Text] [PDF]


Home page
Int J EpidemiolHome page
G. McKeown-Eyssen, C. Baines, D. E. Cole, N. Riley, R. F Tyndale, L. Marshall, and V. Jazmaji
Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR
Int. J. Epidemiol., October 1, 2004; 33(5): 971 - 978.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
P. W. Connelly, G. F. Maguire, and D. I. Draganov
Separation and quantitative recovery of mouse serum arylesterase and carboxylesterase activity
J. Lipid Res., March 1, 2004; 45(3): 561 - 566.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. Senti, M. Tomas, M. Fito, T. Weinbrenner, M.-I. Covas, J. Sala, R. Masia, and J. Marrugat
Antioxidant Paraoxonase 1 Activity in the Metabolic Syndrome
J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5422 - 5426.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
N. Ferre, J. Camps, J. Fernandez-Ballart, V. Arija, M. M. Murphy, S. Ceruelo, E. Biarnes, E. Vilella, M. Tous, and J. Joven
Regulation of Serum Paraoxonase Activity by Genetic, Nutritional, and Lifestyle Factors in the General Population
Clin. Chem., September 1, 2003; 49(9): 1491 - 1497.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
X. Wang, Z. Fan, J. Huang, S. Su, Q. Yu, J. Zhao, R. Hui, Z. Yao, Y. Shen, B. Qiang, et al.
Extensive Association Analysis Between Polymorphisms of PON Gene Cluster With Coronary Heart Disease in Chinese Han Population
Arterioscler. Thromb. Vasc. Biol., February 1, 2003; 23(2): 328 - 334.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
G. K. Marathe, G. A. Zimmerman, and T. M. McIntyre
Platelet-activating Factor Acetylhydrolase, and Not Paraoxonase-1, Is the Oxidized Phospholipid Hydrolase of High Density Lipoprotein Particles
J. Biol. Chem., January 31, 2003; 278(6): 3937 - 3947.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
N. Ferre, J. Camps, E. Prats, E. Vilella, A. Paul, L. Figuera, and J. Joven
Serum Paraoxonase Activity: A New Additional Test for the Improved Evaluation of Chronic Liver Damage
Clin. Chem., February 1, 2002; 48(2): 261 - 268.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
P. K. Shah, S. Kaul, J. Nilsson, and B. Cercek
Exploiting the Vascular Protective Effects of High-Density Lipoprotein and Its Apolipoproteins: An Idea Whose Time for Testing Is Coming, Part I
Circulation, November 6, 2001; 104(19): 2376 - 2383.
[Full Text] [PDF]


Home page
J. Lipid Res.Home page
R. J. Brushia, T. M. Forte, M. N. Oda, B. N. La Du, and J. K. Bielicki
Baculovirus-mediated expression and purification of human serum paraoxonase 1A
J. Lipid Res., June 1, 2001; 42(6): 951 - 958.
[Abstract] [Full Text]


Home page
J. Lipid Res.Home page
I. Leviev, S. Deakin, and R. W. James
Decreased stability of the M54 isoform of paraoxonase as a contributory factor to variations in human serum paraoxonase concentrations
J. Lipid Res., April 1, 2001; 42(4): 528 - 535.
[Abstract] [Full Text]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Senti, M. Tomas, J. Marrugat, R. Elosua, and f. t. REGICOR Investigators
Paraoxonase1-192 Polymorphism Modulates the Nonfatal Myocardial Infarction Risk Associated With Decreased HDLs
Arterioscler. Thromb. Vasc. Biol., March 1, 2001; 21(3): 415 - 420.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Tomas, M. Senti, F. Garcia-Faria, J. Vila, A. Torrents, M. Covas, and J. Marrugat
Effect of Simvastatin Therapy on Paraoxonase Activity and Related Lipoproteins in Familial Hypercholesterolemic Patients
Arterioscler. Thromb. Vasc. Biol., September 1, 2000; 20(9): 2113 - 2119.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. Sen-Banerjee, X. Siles, and H. Campos
Tobacco Smoking Modifies Association Between Gln-Arg192 Polymorphism of Human Paraoxonase Gene and Risk of Myocardial Infarction
Arterioscler. Thromb. Vasc. Biol., September 1, 2000; 20(9): 2120 - 2126.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. W. James, I. Leviev, and A. Righetti
Smoking Is Associated With Reduced Serum Paraoxonase Activity and Concentration in Patients With Coronary Artery Disease
Circulation, May 16, 2000; 101(19): 2252 - 2257.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
C Aubo, M Senti, J Marrugat, M Tomas, J Vila, J Sala, and R Masia
Risk of myocardial infarction associated with Gln/Arg 192 polymorphism in the human paraoxonase gene and diabetes mellitus
Eur. Heart J., January 1, 2000; 21(1): 33 - 38.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 1999 by the American Society for Biochemistry and Molecular Biology.